RSClin Delivers More Precise Assessment of Distant Recurrence Risk and Chemo Benefit in Early Breast Cancer
December 11th 2020
The clinical tool RSClin™, which integrates the 21-gene expression assay and clinical pathologic features, was shown to provide more prognostic information than the 21-gene recurrence score or clinical pathologic features alone and a more precise prediction of absolute chemotherapy benefit in node-negative early breast cancer.